Tenet Healthcare (THC) Benefiting from Capital Return Potential, Says Wells Fargo

Core Viewpoint - Tenet Healthcare Corporation (NYSE:THC) is identified as one of the undervalued momentum stocks, experiencing significant stock price appreciation following its Q4 update, with Wells Fargo raising its price target and maintaining an Overweight rating [1][2]. Financial Performance - For Q4, Tenet reported revenue of $5.53 billion, exceeding the consensus estimate of $5.47 billion by 1% [2]. - Adjusted EPS for Q4 grew 37% year-over-year, reaching $4.70, which surpassed the street expectation of $4.05 [2]. - For FY 2026, Tenet guided revenue between $21.5 billion and $22.3 billion, with adjusted EBITDA projected between $4.485 billion and $4.785 billion [2]. - EPS for FY 2026 is expected to range from $16.19 to $18.47, again above the consensus midpoint of $16.46 [2]. Market Reaction - Following the Q4 results announcement on February 11, the stock rallied 17%, indicating strong investor interest [1]. - Several analysts, including Morgan Stanley, RBC Capital, and KeyBanc, raised their price targets for Tenet, reflecting positive market sentiment [3]. - The stock has shown strong performance with a 57% return in 2025 and an additional 16% increase in 2026, trading close to its 52-week high of $235.8 as of February 20 [3].